INTRODUCTION {#s1}
============

Pluripotency is a steady state in which cells can self-renew and remain undifferentiated, retaining the capacity to give rise to derivatives of any germ layer. This cell state is maintained by an intricate gene regulatory network (GRN) that is tightly regulated by a core set of transcription factors (TF): NANOG, OCT4 and SOX2 ([@BIO046367C35]; [@BIO046367C44]; [@BIO046367C50]; [@BIO046367C53]). These three TFs are involved in establishing and maintaining embryonic pluripotency, both in the blastocyst and in cultured embryonic stem (ES) cells ([@BIO046367C7]). This GRN regulates pluripotency by repressing genes involved in differentiation and activating other genes important for pluripotency ([@BIO046367C35]; [@BIO046367C52]). The same GRN also initiates the process of exiting pluripotency by responding to extrinsic and intrinsic signals and changing the regulatory regions and partners these factors bind to (Hoffman et al., 2013; [@BIO046367C25]; [@BIO046367C32]; [@BIO046367C40]).

ES cells can be maintained in different stages of differentiation, the most studied being ground, naïve and primed pluripotent cells ([@BIO046367C24]; Morgani et al., 2017; [@BIO046367C36]). These states are defined so that they can be maintained and passaged *in vitro* indefinitely: the first with Leukemia Inhibitory Factor (LIF) and 2i (MEK and GSK3 inhibitors), the second with LIF and serum ([@BIO046367C57]), and the latter with Activin and FGF ([@BIO046367C51]). However, while ground and naïve pluripotent cells contribute to all embryonic lineages in blastocyst chimeras, cells in the primed state have lost this potential ([@BIO046367C13]). In ground pluripotent ES cells, NANOG is highly and homogeneously expressed, while in the primed ES cells NANOG expression levels fluctuate. Transition between these two cell states determines the onset of differentiation. In fact, it has been demonstrated that lowering levels of *Nanog* expression in ES cells triggers differentiation and its overexpression is sufficient to maintain the cells in a LIF-independent pluripotent state ([@BIO046367C8]). In spite of multiple studies that have addressed ES cell differentiation ([@BIO046367C31]; [@BIO046367C42]; [@BIO046367C52]), the role of NANOG during the exit from pluripotency *in vivo* is still not well understood ([@BIO046367C35]; [@BIO046367C49]). During implantation, *Nanog* disappears from the epiblast and is re-expressed in the proximal posterior region of the epiblast after implantation, the region in which gastrulation starts ([@BIO046367C19]). Thus, we hypothesized that *Nanog* not only has a role in pluripotency maintenance, but also in defining lineage commitment upon gastrulation ([@BIO046367C31]). We have recently shown that, at the onset of gastrulation, *Nanog* has a determinant role in repressing primitive hematopoiesis and Hox genes expression ([@BIO046367C28] preprint; [@BIO046367C45]).

To gain further insight into the roles of *Nanog* beyond pluripotency*,* we studied the effects of altering the levels of NANOG in different ES cell lines and in mouse embryos. By combining the analysis of different RNA-seq data sets, we found that *Pou3f1* expression is regulated by *Nanog*. *Pou3f1*, which encodes a TF involved in promoting neural fate, is initially expressed throughout the epiblast at early implantation stages ([@BIO046367C48]; [@BIO046367C58]). However, at the onset of gastrulation when *Nanog* is re-expressed in the embryo ([@BIO046367C54]), its expression becomes quickly restricted to the anterior epiblast. While the role of POU3F1 in antagonizing extrinsic neural inhibitory signals is well known ([@BIO046367C58]), little information is available about the transcriptional regulation of this gene in the early stages of gastrulation. By deleting NANOG binding sites located next to the *Pou3f1* locus, we observed that *Nanog* prevents the expression of *Pou3f1* in the posterior region of the gastrulating embryo. Therefore, we present a previously unknown mechanism by which *Nanog* constrains *Pou3f1* expression to the anterior region of the embryo, a necessary step for its role in neural development.

RESULTS {#s2}
=======

Lack of *Nanog* leads to upregulation of anterior genes at the exit from naïve pluripotency {#s2a}
-------------------------------------------------------------------------------------------

To explore the role of *Nanog* and to identify putative targets during the transition from pluripotency to lineage specification, we analyzed expression changes in ES cells mutant for *Nanog* and compared them to the parental wild-type ES cell line as control ([@BIO046367C8]). Cells were first cultured with 2i/LIF/KOSR and subsequently changed to serum to induce exit from pluripotency ([@BIO046367C20]; [@BIO046367C30]). To follow the earliest events taking place, we sampled the cultures at 0, 12, and 24 h ([Fig. 1](#BIO046367F1){ref-type="fig"}A; [Table S1](Table S1)). Then, we performed RNA-seq and selected genes that changed their expression dynamics from 0--24 h. We identified genes repressed by *Nanog* as those with stable expression in control ES cells but increased expression in *Nanog* KO cells along time ([Fig. 1](#BIO046367F1){ref-type="fig"}B), and genes that are positively regulated by *Nanog* as those activated in controls but unchanged in mutant cells ([Fig. 1](#BIO046367F1){ref-type="fig"}C). Fig. 1.**Early transcriptional response to *Nanog* at the naïve to primed transition.** (A) Schematic representation of the experimental setup to address transcriptional changes of control and *Nanog* mutant ES cells as they transition from the naïve to the primed state. Samples in triplicate were taken in naïve conditions (2i+LIF) and after 12 or 24 h of growth in serum. (B,C) Predicted outcome of the change in expression of genes repressed (B) or activated (C) by *Nanog* during priming of ES cells. (D) Volcano plot depicting gene expression changes of control ES cells compared to *Nanog* KO cells in naïve conditions (0 h). In blue, genes upregulated in *Nanog* KO cells, and in orange genes upregulated in control cells (0.5\<LogFC\<0.5). In grey genes that have less than \[0.5\] Log Fold Change (LogFC). Core pluripotency factors are indicated. (E,F) Graphs showing the normalized expression values (average CPM) of genes that are upregulated in *Nanog* mutant cells across time but not in controls (E, repressed by *Nanog*), or genes that are upregulated in control cells but not in *Nanog* mutant (F, activated by *Nanog*). (G) Heatmap comparing the expression profiles of both set of genes, with representative examples of neural (top) or mesodermal (bottom) genes included in these sets indicated on the right. The set of 89 genes upregulated in *Nanog^KO^* across time is represented in the upper section of the heatmap. The set of 55 genes upregulated in control wild-type cells across time is represented in the lower section of the heatmap.

Principal component analysis (PCA) of the RNA-seq data showed a clear separation of the samples based on the genotype of the cells (dim1, [Fig. S1](Fig. S1)) and timing of differentiation (dim2, [Fig. S1](Fig. S1)). The genotypic difference resulted in close to 43% variability, whereas timing of differentiation explained 26% of the variability. Interestingly, the comparison at time 0 between control and *Nanog* KO ES cells showed minimal differences in the expression of core pluripotency genes like *Oct4* or *Sox2* ([Fig. 1](#BIO046367F1){ref-type="fig"}D). The similarities between *Nanog* KO and wild-type cells in the pluripotent stage agree with previous observations on the dispensability of *Nanog* at the pluripotent state ([@BIO046367C8]). We analyzed changes in gene expression, factoring in their expression over time, and identified two clusters with the predicted pattern of change ([Fig. 1](#BIO046367F1){ref-type="fig"}E,F). Genes that are upregulated in differentiating *Nanog* mutant cells but not in controls are enriched in neural specifiers such as *Pou3f1*, *Sox8* or *Fgf3* ([Fig. 1](#BIO046367F1){ref-type="fig"}G; [Table S1A](Table S1A)) ([@BIO046367C5]; [@BIO046367C38]; [@BIO046367C58]). On the other hand, genes that fail to be upregulated in mutant cells are involved in mesoderm development, such as *Mef2c*, *Hand2* or *Tbx2* ([Fig. 1](#BIO046367F1){ref-type="fig"}G; [Table S1B](Table S1B)). This analysis indicates that *Nanog* might be involved in the repression of genes implicated in the development of the anterior-neural fate while promoting posterior-mesodermal fate at the exit from pluripotency in ES cells.

RNA-seq data reveal *Pou3f1* as a primary target for repression by NANOG in gastrulating mouse embryos {#s2b}
------------------------------------------------------------------------------------------------------

To further explore the putative role of *Nanog* in neural anterior fate *in vivo*, we took advantage of published E6.5 embryo single-cell RNA-sequencing (scRNA-seq) data ([@BIO046367C32]; [@BIO046367C46]). E6.5 is the stage at which *Nanog* is re-expressed in the posterior part of the mouse embryo ([@BIO046367C19]) and several genes including *Sox2* or *Pou3f1* are already restricted to the epiblast. We merged two single cell RNA-seq expression data sets and selected those single cells expressing Nanog above 0.4 cpm. The expression of all the genes with 0.4 cpm in at least four cells of at least two samples were adjusted with a linear mixed effect model to the expression of *Nanog* ([Tables S1C](Tables S1C)[, S1D](, S1D)). Next, we established the correlation of all expressed genes to that of *Nanog* ([Fig. 2](#BIO046367F2){ref-type="fig"}A; [Tables S1C](Tables S1C),[D](D)). These results confirmed our previous observations in cultured cells. Genes that correlated positively with *Nanog* were related to gastrulation and mesoderm formation, such as *Fgf8*, *Nodal* or *Eomes* ([Fig. 2](#BIO046367F2){ref-type="fig"}B; [Table S1C](Table S1C)). Genes that negatively correlated with *Nanog* include *Pou3f1* and other neural genes such as *Nav2* ([Fig. 2](#BIO046367F2){ref-type="fig"}B; [Fig. S2A](Fig. S2A), [Table S1D](Table S1D)). Other early anterior genes, such as *Sox2*, did not show any correlation with *Nanog* levels ([Fig. S2B](Fig. S2B)), suggesting that *Nanog* might not have a broad impact on anterior specification, but rather has a specific effect on certain genes. Interestingly, among the negatively correlated genes we also found *Utf1* ([Fig. 2](#BIO046367F2){ref-type="fig"}B), a pluripotency associated gene that is restricted to the anterior region of the embryo during gastrulation and to extraembryonic tissues ([@BIO046367C39]). Enrichment analysis of the clustered genes matching the Jansen tissues gene set library ([@BIO046367C10]; [@BIO046367C26]), allowed us to observe that negatively correlated genes included many genes related to neural development (spinal cord, frontal lobe), and with a lower z-score than endodermal tissues (gut, intestine) ([Fig. S2C](Fig. S2C)). Genes that positively correlate with *Nanog* expression included many genes related to mesodermal tissues (monocyte, B lymphoblastoid cell, bone) ([Fig. S2D](Fig. S2D)). Fig. 2.**Integration of different RNA-seq datasets to identify transcriptional targets of *Nanog*.** (A) Schematic representation of an E6.5 embryo indicating the diminishing levels of *Nanog* towards the distal region of the embryo by a black triangle. Red and green triangles represent the positive and negative correlations, respectively, between *Nanog* and any other given gene. (B) Correlation values of the genes that show the highest statistical correlation with *Nanog* (green, negative; red, positive) in two different mouse embryo single cell RNA-seq data sets ([@BIO046367C32]; [@BIO046367C46]). (C) List of the most downregulated genes in *Nanog^tg^* E7.5 embryos where expression of *Nanog* was induced (dox treated) as compared to controls ([@BIO046367C28] preprint). Bars indicate the log fold change (LFC) of the differences in expression between *Nanog* induced and control embryos. (D) *In situ* hybridization for *Nanog*, *Pou3f1* and *Sox2* of *Nanog^tg^* embryos treated (+dox) or untreated (−dox) with doxycycline. *n*=5. Scale bars: 300 µm. (E) Venn diagram showing the intersection of the different RNA-seq datasets analyzed. In blue are all genes significantly upregulated upon *Nanog* loss of function in ES cells during transition to the primed state (this work); in green, genes that are negatively correlated with *Nanog* in embryo single cell RNA-seq ([@BIO046367C32]; [@BIO046367C46])*;* and in purple, genes downregulated upon expression of *Nanog* in E7.5 embryos ([@BIO046367C28] preprint). Genes found in all three groups are indicated.

We next addressed the effect of expressing *Nanog* throughout the early embryo when using an inducible tetON transgenic model (*Nanog*^tg^) in which *Nanog* expression is induced by the administration of doxycycline (dox) ([@BIO046367C41]). We analyzed bulk RNA-seq data of embryos where *Nanog* was induced from E4.5 to E7.5 and examined changes in gene expression using untreated females of the same genotype as controls ([@BIO046367C28] preprint). In this dataset, many genes involved in the early aspects of embryo pattering, such as Hox genes, were downregulated ([@BIO046367C28] preprint), but the most strongly downregulated gene when *Nanog* was expressed throughout the early embryo was *Pou3f1* ([Fig. 2](#BIO046367F2){ref-type="fig"}C)*.* The expression of other anterior neural genes, for example *Sox2*, *Hesx1* or *Zic3*, was not changed. We confirmed these observations by wholemount *in situ* hybridization of treated and untreated E7.5 *Nanog*^tg^ embryos. Induction of *Nanog* led to a partial downregulation of *Pou3f1* in the anterior epiblast of treated embryos, while expression of *Sox2* was unchanged ([Fig. 2](#BIO046367F2){ref-type="fig"}D). Interestingly, when *Nanog^tg^* embryos were recovered at E9.5 after treatment with dox from E6.5, they presented craniofacial defects (white arrowheads) that might be a direct consequence of the deregulation of yet to be identified *Nanog* target genes ([Fig. S2E](Fig. S2E)).

We merged the data from these previous transcriptomic analysis, finding for example that genes whose expression positively correlated with that of *Nanog* in E6.5 single cells and that were upregulated in dox-treated *Nanog*^tg^ embryos were mostly related to early gastrulation and mesoderm specification, such as *Eomes*, *Fgf8*, *Tdgf1* (*Cripto*) or *Mixl1*. However, only three genes were shared by those upregulated in *Nanog* KO ES cells during early differentiation, genes having a significant negative correlation with *Nanog* in E6.5 single cell transcriptomics, and that were downregulated in E7.5 *Nanog* gain-of-function embryos: *Pou3f1*, *Lrp2* and *Clic6* ([Fig. 2](#BIO046367F2){ref-type="fig"}E). Interestingly, *Lrp2* and *Clic6* are expressed in primitive endoderm and late derivatives ([@BIO046367C15]; [@BIO046367C47]), which are lineages in which *Nanog* has a well-defined negative regulatory role ([@BIO046367C9]; [@BIO046367C12]; [@BIO046367C55]). Therefore, *Pou3f1* is a prime candidate to be a direct target of *Nanog*, mediating its role in suppressing anterior epiblast fate.

*Nanog* expression impairs neural differentiation *in vitro* {#s2c}
------------------------------------------------------------

To confirm whether *Nanog* is blocking anterior fate progression, we derived ES cells from the *Nanog*^tg^ line and differentiated them towards anterior neural fate ([@BIO046367C16], [@BIO046367C17]), culturing them with or without dox for up to 6 days. Analysis of gene expression by RT-qPCR showed that upon induction of *Nanog*, neural specification genes (*Pou3f1*, *Sox1*, *Pax6* and *Otx2*) were not upregulated during the differentiation process to the same extent as in control-treated cells. *Sox2*, which has roles both in pluripotency and in early neural development, showed a similar pattern of expression by qPCR in both *Nanog*^tg^ +dox and −dox ([Fig. 3](#BIO046367F3){ref-type="fig"}A). Immunofluorescence of TUJ1, revealed lack of differentiation at a protein level in the differentiation of *Nanog*^tg^ cells treated with dox ([Fig. 3](#BIO046367F3){ref-type="fig"}B). When cells were differentiated towards a more posterior neural fate by treatment with high doses of retinoic acid ([@BIO046367C16], [@BIO046367C17]), differences in the expression of neural markers were less marked, although following a similar trend ([Fig. S3](Fig. S3)). We also observed a reduction in the expression of *Hoxa1*, a marker for posterior neural (hindbrain) fate ([Fig. S3](Fig. S3)), in line with recent findings ([@BIO046367C11]; [@BIO046367C28] preprint). These results indicate that during neural differentiation, *Nanog* prevents the upregulation of genes important for neural specification. Fig. 3.***Nanog* impedes anterior neural differentiation of ES cells.** (A) Expression of selected neural markers, as measured by RT-qPCR, during 6 days of differentiation to anterior neural fate of *Nanog^tg^* ES cells with (+dox, blue) or without (−dox, gray) doxycycline. *n*=3 at each time point; \**P*\<0.01; \*\**P*\<0.001; \*\*\**P*\<0.0001, by Student\'s *t*-test. (B) Immunofluorescence at day 6 of anterior neural differentiation of *Nanog^tg^* ES cells with (+dox) or without (−dox) showing nuclei stained with DAPI in blue, and TUJ1 in green. Scale bars: 100 µM.

A distal NANOG-binding element represses *Pou3f1* expression in the posterior epiblast {#s2d}
--------------------------------------------------------------------------------------

The evidence presented so far suggests that *Pou3f1* is likely a direct transcriptional target of NANOG during anterior-posterior axis specification in the epiblast. To explore this possibility, we analyzed published ChIP-seq data for NANOG binding in ES and epiblast-like cells (EpiLCs) ([@BIO046367C33]). This work describes a broad resetting of NANOG-occupied genomic regions in the transition from ES cells to EpiLCs, resembling the developmental progress from the naïve inner cell mass of the blastocyst to the primed epiblast at gastrulation. We examined the *Pou3f1* locus and identified three prominent regions of NANOG binding at 11.5 and 9 kilobases (kb) upstream and 9 kb downstream from the transcription start site. Interestingly, NANOG binds these regions in EpiLC but not in ES cells, suggestive of a specific input of *Nanog* on *Pou3f1* in the epiblast but not at earlier pluripotent stages ([Fig. 4](#BIO046367F4){ref-type="fig"}A). Fig. 4.**Deletion of a NANOG bound region in the *Pou3f1* locus expands its expression in the posterior epiblast.** (A) *Pou3f1* genomic region on chromosome 4 showing binding of NANOG as determined by ChIP-seq in ES cells (ESC) or EpiLC after one (D1) or two (D2) days of differentiation D2. Data was obtained from [@BIO046367C33]. (B) Percentage of embryos without (wild-type genotype) or with the expected deletion (del. genotype) recovered at E6.5 after microinjection of Cas9 and pairs of sgRNAs targeting each of the three NANOG bound regions in the *Pou3f1* locus (−11.5 kb, −9 kb, +9 kb). In gray, percentage of embryos showing a normal expression pattern of *Pou3f1* (wild-type phenotype) and in blue those showing expansion of expression in the posterior region of the epiblast (expanded expression phenotype). Below, Fisher's exact test *P*-value for differences of expression patterns (phenotypes) between genotypes. (C) *In situ* hybridization for *Pou3f1* in E6.5 embryos showing the normal expression pattern (wild-type phenotype) and the extended expression in the posterior epiblast (white arrow) due to the deletion by transient transgenics of the +9 kb NANOG-bound genomic region (expanded expression phenotype). The extent of *Pou3f1* expression is indicated by a dashed white line. (D) Sequence of the +9 kb NANOG-bound genomic region from *Pou3f1* (mm10, chr4:124,666,818-124,667,185). gRNAs are shown in blue, the consensus NANOG binding motif in black, and the region deleted in the stable +9 kb deletion mouse line in grey. (E) *In situ* hybridization for *Pou3f1* in heterozygous (left) and homozygous (right) E6.5 embryos from the +9 kb deletion mouse line. White arrowhead indicates the posterior expansion in expression observed in homozygote embryos. The number of embryos showing an expansion of *Pou3f1* expression is indicated for each genotype. Scale bars (C,E): 300 µm.

We hypothesized that the deletion of the NANOG bound regions would de-repress *Pou3f1* and therefore expand its expression domain towards the posterior region of the embryo at E6.5. To investigate this hypothesis, we separately deleted each of the three NANOG bound regions we identified at the *Pou3f1* locus by CRISPR/Cas9 genome editing in a transient transgenic embryo assay. Embryos microinjected with Cas9-gRNAs ribonucleoproteins were recovered at E6.5, processed for wholemount *in situ* hybridization, and subsequently genotyped for the expected deletion ([Fig. S4](Fig. S4)). This assay showed that only deletion of the +9 kb downstream region caused a reproducible change in *Pou3f1* expression, consisting in a posterior expansion of its expression domain in the epiblast ([Fig. 4](#BIO046367F4){ref-type="fig"}B,C). To further confirm this observation, we generated a stable mouse line carrying the deletion of the +9 kb NANOG bound region ([Fig. 4](#BIO046367F4){ref-type="fig"}D). Mice homozygous for the deletion were viable and fertile, which was not completely unexpected as homozygous null *Pou3f1* mice survive up to birth ([@BIO046367C6]). We crossed mice heterozygous and homozygous for the deletion and compared littermates for the expression of *Pou3f1* by wholemount *in situ* hybridization. We observed that three out of five homozygous embryos presented a phenotype of posterior expansion while none of the heterozygous embryos did so ([Fig. 4](#BIO046367F4){ref-type="fig"}E). These results show that the +9 kb NANOG bound region is important for the restriction of *Pou3f1* expression to the anterior epiblast.

DISCUSSION {#s3}
==========

The transition from pluripotency towards early differentiation that occurs during the initial stages of mammalian embryonic development can be recapitulated *in vitro*, at least partially, under defined culture conditions ([@BIO046367C18]; [@BIO046367C36]). This provides an opportunity to study and follow different pluripotent states, as cells move from the naïve or ground state, equivalent to the epiblast of the blastocyst, to a primed state that more closely resembles the early post-implantation embryo, where first lineage decisions take place ([@BIO046367C56]). The role of a core set of transcription factors (that includes OCT4, NANOG or SOX2) controlling the establishment and maintenance of embryonic pluripotency has been extensively studied ([@BIO046367C7]). Moreover, recent studies indicate that these same factors can play important roles in regulating the exit from pluripotency towards committed states ([@BIO046367C13]) as well as later developmental decisions in the embryo ([@BIO046367C2]; [@BIO046367C28] preprint; [@BIO046367C45]).

In this work, we sought to capture the first steps in the differentiation of naïve ES cells to assess the role of *Nanog* in the exit from pluripotency. We observed that globally, *Nanog* represses the differentiation of the anterior fate while promoting posterior differentiation. In an effort to identify direct transcriptional targets of NANOG in this process, we merged three sets of data: transcriptomic data from naïve-to-primed differentiation of *Nanog* mutant ES cells; single-cell RNA-seq data from E6.5 embryos ([@BIO046367C32]; [@BIO046367C46]); and transcriptional analysis of the forced expression of *Nanog* in E7.5 embryos ([@BIO046367C28] preprint). Only three genes were identified that met the requirements to be negatively regulated by *Nanog* (upregulated during differentiation of *Nanog* KO cells, negatively correlated with *Nanog* in scRNA-seq data, and downregulated upon *Nanog* expression in embryos). Two of them, *Lrp2* and *Clic6*, are most prominently expressed in the primitive endoderm and later in other endoderm derivatives ([@BIO046367C37]), and in fact LRP2 had been previously identified as a marker of primitive endoderm precursors of the blastocyst ([@BIO046367C15]). This fits well with the known role of *Nanog* in the epiblast/primitive endoderm decision occurring in the preimplantation embryo ([@BIO046367C4]; [@BIO046367C14]) and suggests that *Lrp2* and *Clic6* could be directly repressed by NANOG in epiblast cells of the blastocyst.

The third gene identified as a potential NANOG target is *Pou3f1*. This gene encodes a POU family transcription factor, initially expressed throughout the epiblast of E6.5 embryos and later restricted to the anterior epiblast at E7.5 and afterwards, to the anterior neural tube ([@BIO046367C22]; [@BIO046367C59]). *Pou3f1* has also been shown to drive the progression of neural differentiation both in ES cells and in epiblast like stem cells (EpiLCs) through the activation of intrinsic neural lineage genes such as *Sox2* or *Pax6* ([@BIO046367C48]; [@BIO046367C58]). *Pou3f1* is strongly downregulated in embryos in which we induce the expression of *Nanog*, and we observe the same in ES cells differentiated towards neural fates. Interestingly, this effect is more pronounced when ES cells are directed to anterior/forebrain identities rather than posterior/hindbrain fates ([@BIO046367C16]; [@BIO046367C17]), resembling the dynamics of *Pou3f1* expression in the developing neural tube ([@BIO046367C59]).

Analysis of published ChIP-seq data in ES and EpiL cells ([@BIO046367C33]) allowed us to identify three genomic regions that could be mediating the transcriptional repression of *Pou3f1* by NANOG. It is noteworthy that these sites are not bound in ES cells but only in EpiLCs, indicating that NANOG is not simply repressing *Pou3f1* as part of the core pluripotency program, but involved in fine-tuning the timing of its expression once differentiation programs are initiated at the primed state. We detected expansion of *Pou3f1* expression to the posterior epiblast only when the +9 kb region was deleted. However, this does not rule out a possible input of the other two regions (−11.5 kb and −9 kb); had all three regions been deleted in the same embryo, we might have observed a more robust de-repression of *Pou3f1*.

The results we describe here, together with our previous observations regarding the function of *Nanog* in primitive hematopoiesis ([@BIO046367C45]), suggest that *Nanog* has an active role in the primed epiblast as a brake for ongoing lineage determination. Apparently, this occurs through well-known neural (*Pou3f1*) or mesodermal (*Tal1*; [@BIO046367C45]) specifiers, but it is tempting to speculate, based on our observations for *Lrp2* and *Clic6*, that it is also occurring in endodermal lineages. Only when *Nanog* expression is extinguished, transcriptional repression of these epiblast-specific targets lifted, and differentiation allowed to proceed. Understanding the regulatory mechanism that controls the re-expression of *Nanog* in the epiblast ([@BIO046367C19]) and how it is definitively silenced will allow us to better understand how pluripotency is dismantled and how particular lineage specific programs come to be deployed.

MATERIALS AND METHODS {#s4}
=====================

ES cell culture and differentiation {#s4a}
-----------------------------------

ES cells were maintained in serum-free conditions with Knockout serum replacement (Thermo Fisher Scientific), LIF (produced in-house), and 2i (CHIR-99021, Selleckchem; and PD0325901, Axon) over inactive mouse embryonic fibroblast (MEFs). The *Nanog*^KO^ (BT12) and their parental wild-type control (E14Tg2a) ES cells were kindly provided by Ian Chambers (MRC Centre for Regenerative Medicine, Edinburgh) and Austin Smith (Wellcome-MRC Cambridge Stem Cell Institute) ([@BIO046367C8]). The *Nanog* gain-of-function ES cells were derived from the *Nanog/rtTA* mouse line following standard procedures ([@BIO046367C34]). Karyotyping of the obtained lines was performed by the Pluripotent Cell Technology Unit at CNIC.

*Nanog*^tg^ ES cells were differentiated to anterior (forebrain) or posterior (hindbrain) neural lineages as described ([@BIO046367C16], [@BIO046367C17]). Cells were grown in N2B27 media supplemented with 10 ng/ml bFgf (R&D) for the first 3 days (d1--d3), and then from day 3 to 6 in N2B27 without growth factors for forebrain differentiation, or in N2B27 supplemented with 10 nM retinoic acid for hindbrain differentiation. A Tuj1 monoclonal antibody (Promega \#G7121, dilution 1:100) was used to assess neuronal differentiation. All cell lines have been tested for contamination at the CNIC Cell Culture Unit.

RNA-seq {#s4b}
-------

RNA from *Nanog^KO^* ES cells and their parental line was extracted using the RNeasy Mini Kit (Qiagen) and then reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Library preparation (New England Biolabs Nest Ultra RNA library prep Kit) and single read next generation sequencing (Illumina HiSeq 2500) were performed at the Genomics Unit at Centro Nacional de Investigaciones Cardiovasculares (CNIC).

Sequencing reads were processed by means of a pipeline that used FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>) to asses read quality, and Cutadapt v1.3 ([@BIO046367C29]) to trim sequencing reads, eliminating Illumina adaptor remains and to discard reads that were shorter than 30 bp. The resulting reads were mapped against the mouse transcriptome (GRCm38 assembly, Ensembl release 76) and quantified using RSEM v1.2.20 ([@BIO046367C27]). Raw expression counts were processed with an analysis pipeline that used Bioconductor packages EdgeR ([@BIO046367C43]) for normalization (using TMM method) and differential expression testing, and ComBat ([@BIO046367C23]) for batch correction. Only genes expressed at a minimal level of 1 count per million, in at least three samples, were considered for differential expression analysis. Changes in gene expression were considered significant if their Benjamini and Hochberg adjusted *P*-value (FDR) was lower than 0.05.

RNA-seq data is available at the Gene Expression Omnibus (GEO) database under accession number GSE138818.

Bioinformatic analysis {#s4c}
----------------------

Two data sets from different mouse embryo single cell RNA-seq experiments ([@BIO046367C32]; [@BIO046367C46]) were normalized by quantiles and batch corrected. After merging the two datasets, genes with zero-variance were eliminated and counts were log2 transformed and scaled. Then, datasets were normalized using the quantiles method and batch corrected. Single cell clustering patterns were visualized after dimensionality reduction with the R package Rtsne. For correlation of genes with *Nanog* we used the slope of the line adjusted to the points per sample. For plotting we used ggPlot package from R. We separated the plots by sample. Statistical analysis was developed in R. RNA-seq data from E7.5 *Nanog^tg^* embryos was previously described ([@BIO046367C28] preprint). The intersection analysis of the genes coming from different RNA-seq datasets was performed with the web tool from Bioinformatics and Evolutionary Genomics (<http://bioinformatics.psb.ugent.be/webtools/Venn/>).

RT-qPCR assays {#s4d}
--------------

RNA was isolated from ESCs using the RNeasy Mini Kit (Qiagen) and then reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNA was used for quantitative-PCR (qPCR) with Power SYBR^®^ Green (Applied Biosystems) in a 7900HT Fast Real-Time PCR System (Applied Biosystems). Primers for qPCR detailed in [Table S2](Table S2).

Transgenic analysis and mouse models {#s4e}
------------------------------------

For the generation of transgenic embryos, 7-week-old F1 (C57Bl/6xCBA) females were superovulated to obtain fertilized oocytes as described ([@BIO046367C34]). Viable one-cell embryos were microinjected into the pronucleus with commercially available Cas9 protein (30 ng/µl; PNABio) and guide RNAs (sgRNA; 25 ng/µl; Sigma-Aldrich). All those components were previously hybridized in solution to generate ribonucleoprotein complexes. First, we incubated 100 ng/µl of trans-activating crRNA (tracrRNA) and sgRNA for 5 min at 95°C and then for 10 min at room temperature (RT). We then incubated the sgRNAs with the Cas9 for 15 min at RT and stored at 4°C. Injection buffer consisted of Tris 50 nM pH7.4, EDTA 1 nM, H~2~O embryo tested and was filtered through a 0.22 um filter. After injection, embryos were cultured in M16 (Sigma-Aldrich) covered with mineral oil (Nid Oil, EVB) up to the two-cell stage. Living embryos were then transferred into a pseudopregnant CD1 female, previously crossed with a vasectomized male. Embryos were recovered at E6.5 for further analysis, or allowed to progress in order to establish a stable line carrying the deletion of the +9 kb region. sgRNA were designed with an online tool (<http://crispr.mit.edu/>). Details of the sequences for the sgRNAs and primers used for genotyping are shown in [Table S2](Table S2).

We obtained the *Nanog/rtTA* mouse line (*R26-M2rtTA;Col1a1-tetO-Nanog*) ([@BIO046367C41]) from Manuel Serrano (CNIO, Madrid) and Konrad Hochedlinger (Harvard Stem Cell Institute). This is a double transgenic line that carries the *M2-rtTA* gene inserted at the *Rosa26* locus and a cassette containing *Nanog* cDNA under the control of a doxycycline-responsive promoter (tetO) inserted downstream of the *Col1a1* locus. Mice were genotyped by PCR of tail-tip DNA as previously described ([@BIO046367C21]; [@BIO046367C41]).

All mice used in this work were housed and maintained in the animal facility at the Centro Nacional de Investigaciones Cardiovasculares (Madrid, Spain) in accordance with national and European Legislation. Procedures were approved by the CNIC Animal Welfare Ethics Committee and by the Area of Animal Protection of the Regional Government of Madrid (ref. PROEX 196/14).

*In situ* hybridization {#s4f}
-----------------------

Embryos were collected in cold PBS, transferred to 4% PFA, and fixed overnight at 4°C. After washing, embryos were dehydrated in increasing concentrations of PBS-diluted methanol (25%, 50%, 75% and 2X 100%). *In situ* hybridization in wholemount embryos was performed as previously described ([@BIO046367C1]; [@BIO046367C3]). Signal was developed with anti-digoxigenin-AP (Roche) and BM-Purple (Roche). Images were acquired with a Leica MZ-12 dissecting microscope. Primers used for the generation of probes are detailed in [Table S2](Table S2). The expansion of *Pou3f1* expression into posterior territories was scored on images of embryos after wholemount *in situ*. For this, embryos were divided vertically by an imaginary line that separated anterior from posterior halves of the epiblast. If *Pou3f1* expression extended into the posterior half, it was scored as a phenotype.

Statistical analysis {#s4g}
--------------------

Statistical analysis was performed with the use of two-tailed Student\'s unpaired *t*-test analysis (when the statistical significance of differences between two groups was assessed). Fisher's exact test was performed for analysis of contingency tables containing the data of the deleted genotypes and expanded phenotypes. Prism software version 7.0 (GraphPad Inc.) was used for representation and statistical analysis. Enriched functional categories in the mouse gene atlas score was calculated using Enrichr ([@BIO046367C10]; [@BIO046367C26]).
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